JWJing Wang

Jing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Li-Hui Zhang

    Department of Cardiology, Shanxi Academy of Medical Sciences and Shanxi Dayi Hospital, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China

    2 shared publications
  • Qianfeng Xiong

    Department of Cardiology, Fengcheng People's Hospital The Affiliated Fengcheng Hospital of Yichun University Fengcheng Jiangxi province China

    2 shared publications
  • Junke Luo

    Department of Cardiac Intensive Care Unit, Fengcheng People’s Hospital, The Affiliated Fengcheng Hospital of Yichun University, 331100 Fengcheng, Jiangxi, China

    1 shared publication
  • Lei Huang

    Department of Cardiology, Fengcheng People’s Hospital, The Affiliated Fengcheng Hospital of Yichun University, 331100 Fengcheng, Jiangxi, China

    1 shared publication
  • Pengfeng Xiong

    Department of Cardiology, Fengcheng People’s Hospital, The Affiliated Fengcheng Hospital of Yichun University, 331100 Fengcheng, Jiangxi, China

    1 shared publication
  • Shao-Hua Fan

    Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan 030006, Shanxi, China

    1 shared publication

Latest Publications

  • Open Access

    Prognostic Significance of Homocysteine Levels in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Propensity Score Matching and Weighting Analysis

    by Qianfeng Xiong, Shaoyong Chen, Junke Luo, Pengfeng Xiong, Zhenyun Nie, Lei Huang, Yao Wang, Zhen Lei, Lihui Zhang, Jing Wang

    Background: Elevated homocysteine (Hcy) levels have been linked to poorer outcomes in acute coronary syndrome. This study aimed to assess the predictive value of elevated Hcy levels for major adverse cardiac events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Methods: This retrospective cohort study included 183 STEMI patients who underwent primary PCI at a tertiary university hospital in southern China from January 2020 to December 2021. Laboratory values, including Hcy levels, were obtained within 24 hours of admission. Patients were categorized into elevated and normal Hcy groups using a threshold of 12 μmol/L. The study outcome was the occurrence of 6-point MACE, defined as cardiac death, nonfatal myocardial infarction, stroke, ischemia-driven revascularization (PCI or coronary artery bypass grafting), heart failure and all-cause death. Survival analyses were conducted using Kaplan-Meier and Cox proportional hazard methods. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) approaches were employed to minimize bias. Results: The mean age of the patients was 64.8 years, with 76.0% being male. After adjusting with PSM or IPTW, covariate imbalances between the two groups were corrected. Over a median follow-up period of 25.8 months, 55 MACE events occurred, resulting in an event rate of 30.1%. Patients with elevated Hcy levels had a higher incidence of MACE in both unadjusted (hazard ratio [HR] = 2.778; 95% confidence interval [CI]: 1.591–4.850; p < 0.001) and adjusted analyses (PSM: HR = 2.995; 95% CI: 1.397–6.423, p = 0.005; IPTW: HR = 3.2; 95% CI: 1.631–6.280, p < 0.001). Multivariate Cox regression further confirmed that elevated Hcy levels were associated with a worse prognosis across the entire cohort (HR = 1.062, 95% CI: 1.029–1.097, p < 0.001), PSM cohort (HR = 1.089, 95% CI: 1.036–1.145, p < 0.001), and IPTW cohort (HR = 1.052, 95% CI: 1.020–1.086, p = 0.001). Conclusions: Elevated plasma levels of Hcy (≥12 μmol/L) are associated with worse outcomes in STEMI patients undergoing primary PCI, highlighting the potential role of Hcy as a prognostic marker in this population.


  • Open Access

    GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents

    by Qian-Feng Xiong, Shao-Hua Fan, Xue-Wen Li, Yu Niu, Jing Wang, Xin Zhang, Yi-Fan Chen, Ya-Wei Shi, Li-Hui Zhang

    GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1’s effects on the rat coronary artery (RCA) or about the mechanisms underpinning these effects. Here, we report that GLP-1 inhibits depolarization- or thromboxane receptor agonist (U46619)-induced RCA contraction in a dosage-dependent manner. Vasorelaxation was attenuated by denuding the endothelium, L-NAME (nitric oxide synthase inhibitor), and glyburide (KATP channel blocker) but was not affected by indomethacin (cyclooxygenase inhibitor), iberiotoxin [Ca2+-activated K+ channel (KCa) blocker], or 4-aminopyridine (KV channel blocker). Furthermore, GLP-1 increased outward K+ currents by enhancing the KATP channel in rat coronary arterial smooth muscle cells (RCASMCs). These results show that GLP-1 is an endothelial-dependent vasospasmolytic agent in the RCA and imply that the relaxant effect is regulated by enhancing KATP rather than KV or KCa currents in RCASMCs.